Structured evidence table for Chromium Fasting Glucose Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Fasting Glucose Randomized Trial | 1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Randomized Trial | 1 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Randomized Trial | 5 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Randomized Trial | It includes central obesity, insulin resistance, hypertension, and dyslipidemia. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Randomized Trial | Reduced insulin receptor sensitivity leads to a significant decline in insulin efficacy during glucose metabolism, further promoting hyperinsulinemia. | 1 | Ye Jiahui (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials |
| Chromium Fasting Glucose Randomized Trial | [] reported that chromium may improve IR, while other studies have found that mineral supplements have no significant effects on blood sugar, lipids, or PCOS []. | 1 | Ye Jiahui (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials |
| Chromium Fasting Glucose Randomized Trial | [] conducted a case-control study showing that reduced serum zinc concentrations in women with PCOS positively impact metabolic and endocrine systems. | 1 | Ye Jiahui (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials |
| Chromium Fasting Glucose Randomized Trial | 1 2 3 4 5 6 7 8 9 10 11 12 Polycystic ovary syndrome (PCOS) is a prevalent public health concern and one of the most commonly occurring endocrine disorders []. | 1 | Ye Jiahui (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials |
Source documents